T2 Biosystems (TTOO) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

TTOO T2 Biosystems

Watchlist

1.8600
-0.1100-5.58%

Close Oct 1 16:00 ET

1.9100
+0.0500+2.69%

Post 18:25 ET

32.51MMarket Cap0.06P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

T2 Biosystems Highlights New Article Published in The Lancet: Changing the Culture of Blood Culture
Yahoo FinanceSep 23 09:00 ET
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
GlobeNewswireSep 20 09:00 ET
T2 Biosystems Director Sells Shares Worth $133
InvestingSep 17 17:06 ET
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients
GlobeNewswireSep 16 09:00 ET
T2 Biosystems Plans Own Laboratory to Produce Lyme Disease Diagnostic Kits -- Share Down
MT NewswiresSep 9 12:47 ET
T2 Biosystems: Pioneering Rapid Diagnostic Tests Launch
TipRanksSep 9 09:29 ET

Comments

Trytosaveabit

Sep 20 08:01

Update

$T2 Biosystems (TTOO.US)$ Reuters· just
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union

Jaguar8

Sep 20 08:00

NEWS

$T2 Biosystems (TTOO.US)$
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
T2 Biosystems (NASDAQ:TTOO) has successfully defended a key patent for its direct-from-whole blood detection method in the European Union. The opposition, filed in May 2023 by bioMerieux and an undisclosed party, challenged T2 Biosystems' European Patent No. 3 443 124. This patent is important to the company's intellectual property portfolio...

Trytosaveabit

Sep 16 08:01

News

$T2 Biosystems (TTOO.US)$ Reuters· 1 min ago
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients

Jaguar8

Sep 9 08:02

NEWS

$T2 Biosystems (TTOO.US)$
T2 Biosystems Provides Updates on its New Product Development Pipeline Progress
T2 Biosystems (NASDAQ:TTOO) has provided updates on its new product development pipeline, focusing on direct-from-blood diagnostic tests for antimicrobial resistance, pediatric Candida infections, Lyme disease, and Candida auris. Key highlights include:
1. Finalizing a 510(k) application for the T2Resistance® Panel, planned for Q4 2024 FDA submission.
2. Pending FDA clearance for expande...